Results 131 to 140 of about 34,891 (226)

T‐bet Fate Mapping Reveals Gestational Stage‐Specific Transcriptional Adaptation of Decidual NK Cells

American Journal of Reproductive Immunology, Volume 95, Issue 3, March 2026.
ABSTRACT Problem Natural killer (NK) cells are critical regulators of immune balance at the maternal–fetal interface. T‐bet (Tbx21) is a key transcription factor shaping NK cell effector functions, yet its role in decidual NK (dNK) cell adaptation across gestation remains unclear.
Mona A. Mohamed, Yan Li, Andrea K. Wegrzynowicz, Payton N. Lindner, Jessica Vazquez, Gladys E. Lopez, Aleksandar K. Stanic   +6 more
wiley   +1 more source

Combination of artesunate and ruxolitinib suppresses T cell leukemia/lymphoma proliferation via the JAK STAT pathway. [PDF]

Sci Rep
Yuan Y, Li Y, Li J, Wang S, Luo F, Huang C, Yang J, Hu Y, Jia Y, Wang S.   +9 more
europepmc   +1 more source

Targeting MCL‐1 and MAPK overcomes venetoclax resistance in FLT3‐ITD‐positive AML cells harbouring activating PTPN11 (SHP‐2) mutations

British Journal of Haematology, Volume 208, Issue 3, Page 905-915, March 2026.
Summary Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients ...
Maximilian Fleischmann, Ole Hansen, Diana Voigtländer, Julia Bechwar, Lenny‐Joseph Schwietzer, Sanja Bahr, Ulf Schnetzke, Mike Fischer, Florian H. Heidel, Tina M. Schnöder, Jörg P. Müller, Andreas Hochhaus, Sebastian Scholl   +12 more
wiley   +1 more source

Histone deacetylase 3 promotes hypoxia-induced human pulmonary arterial smooth muscle cell proliferation by modulating the CSF2-JAK2-STAT5 signaling pathway. [PDF]

Hum Cell
Zhang J, Fan Y, Gao Y, Jin Y.
europepmc   +1 more source

Protein tyrosine phosphatases as emerging targets for cancer immunotherapy

British Journal of Pharmacology, Volume 183, Issue 6, Page 1233-1249, March 2026.
Abstract Contemporary strategies in cancer immunotherapy, despite remarkable success, remain constrained by inherent limitations such as suboptimal patient responses, the emergence of drug resistance, and the manifestation of pronounced adverse effects. Consequently, the need for alternative strategies for immunotherapy becomes clear.
Zihan Qu, Jiajun Dong, Zhong‐Yin Zhang
wiley   +1 more source

The E3 ligases Itch and WWP2 regulate autoimmune neuroinflammation by controlling T_H2 to T_H17 cell conversion via interleukin-4-STAT5 axis in mice. [PDF]

Nat Commun
Zhao M, Zhang C, Zhang X, Mu Q, Li Q, Liu YC.   +5 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1250-1270, March 2026.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Modulation of immune responses by elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis: data from a compassionate use program. [PDF]

Respir Res
Lucca F, Pianazzola A, Meneghelli I, Catanzaro G, Sabbioni G, Tridello G, Hristodor AM, De Luca E, Menichetti G, Breveglieri G, Altieri MT, Bordicchia M, Fabrizzi B, Ferretti E, Lippi G, Ros M, Borgatti M, Cipolli M, Bezzerri V.   +18 more
europepmc   +1 more source

Dasatinib Produces Lengthy Remissions of Extramedullary Leukemia: A Retrospective Observational Study

European Journal of Haematology, Volume 116, Issue 3, Page 302-310, March 2026.
ABSTRACT Since 2004, patients receiving imatinib with relapse in non‐marrow sites were given dasatinib to preserve control of leukemic marrow. Remissions in CNS and other organs began to be reported and are continuously observed to present. With resistance to one BCR::ABL1 tyrosine kinase inhibitor and sensitivity to a dual BCR::ABL1/SRC inhibitor ...
I. Cunningham, R. A. Fisher, J. Yang, Y. Guo, U. Bommhardt   +4 more
wiley   +1 more source

<i>Ascaris lumbricoides</i> antigen exposure modulates T cell activation via regulation of IL-15Rα expression, STAT5 phosphorylation, and promotes differentiation of BCL6^low B cells. [PDF]

Front Immunol
Pushpamithran G, Appelgren D, Gilman RH, Blomgran R.   +3 more
europepmc   +1 more source